Syndax Pharmaceuticals, Inc.SNDXNASDAQ

Revenue (LTM)

$172M

+627.8% YoY

Net Income (LTM)

$-285M

+10.5% YoY

Free Cash Flow

$-323M

Revenue CAGR (5Y)

+157.7%

Marginsdeclining

FCF($0.3B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	140	0	0	24	172↑627.8%
Gross Profit	140	0	0	23	165↑623.6%
Operating Income	26	-152↓678.8%	-230↓51.5%	-340↓47.7%	-273↑19.6%
Net Income	25	-149↓699.1%	-209↓40.2%	-319↓52.3%	-285↑10.5%
EBITDA	27	-146↓644.0%	-209↓43.1%	-314↓50.1%	-252↑19.8%
EPS Diluted	0.48	-2.46↓612.5%	-2.98↓21.1%	-3.73↓25.2%	-3.30↑11.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	222	74↓66.5%	295↑297.3%	154↓47.8%	135↓12.4%
Total Current Assets	448	490↑9.2%	581↑18.6%	603↑3.8%	528↓12.4%
Total Assets	450	497↑10.6%	613↑23.3%	725↑18.3%	530↓26.9%
Total Current Liabilities	21	29↑40.5%	58↑99.9%	104↑78.2%	120↑16.0%
Total Liabilities	41	30↓27.9%	59↑97.0%	437↑644.1%	465↑6.5%
Total Equity	408	467↑14.5%	554↑18.6%	288↓48.0%	65↓77.6%
Total Debt	21	1↓94.5%	2↑40.8%	346↑21046.1%	346↑0.2%
Net Debt	-201	-73↑63.6%	-294↓301.3%	192↑165.2%	212↑10.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	29	-134↓558.9%	-161↓20.1%	-275↓71.2%	-323↓17.5%
Capital Expenditure	-0	-0↓74.4%	0	0	-0
Free Cash Flow	29	-134↓561.7%	-161↓19.9%	-275↓71.2%	-323↓17.6%
Stock-Based Comp	13	16↑20.3%	31↑93.2%	43↑39.0%	48↑10.4%
Net Change in Cash	107	-148↓238.3%	221↑249.8%	-141↓163.9%	-19↑86.4%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance